Mannkind MNKD Afrezza — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mannkind in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Mannkind’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mannkind's afrezza — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mannkind's afrezza — revenue?
- Mannkind (MNKD) reported afrezza — revenue of $15.27M in Q1 2026.
- How has Mannkind's afrezza — revenue changed year-over-year?
- Mannkind's afrezza — revenue increased by 2.6% year-over-year, from $14.89M to $15.27M.
- What is the long-term trend for Mannkind's afrezza — revenue?
- Over 3 years (2022 to 2025), Mannkind's afrezza — revenue has grown at a 19.9% compound annual growth rate (CAGR), from $43.32M to $74.59M.
- What does afrezza — revenue mean?
- This metric represents the total gross revenue generated from the sale of a specific pharmaceutical product or therapeutic line, net of any applicable sales taxes. It serves as a primary indicator of market adoption, commercial traction, and the underlying demand for the company's core inhaled therapeutic offerings. Tracking this revenue stream allows investors to evaluate the growth trajectory and competitive positioning of the product within the broader biopharmaceutical market.